-
Jiahui Health and Gleneagles Hong Kong Hospital Partner for Integrated Healthcare Services
•
China-based Jiahui Health has entered into a strategic partnership with Gleneagles Hong Kong Hospital to enhance remote consultation, patient referral, cross-regional doctor visits, medical communication, and training. The collaboration also focuses on cutting-edge diagnosis and treatment methods, as well as drug use, among other areas. Financial details of the agreement…
-
Saints Sages Surgical Secures Series B Funding to Advance Energy-Based Devices
•
Shanghai-based Saints Sages Surgical Co., Ltd, a leading developer of high-value minimally invasive surgical products, has successfully raised an undisclosed amount in its Series B financing round. The round was led by Qiming Venture Partners, a returning investor, and the funds will be allocated to the research and development of…
-
Hainan Huluwa Pharmaceutical Gets NMPA Approval for Generic Briviact Clinical Study
•
China-based Hainan Huluwa Pharmaceutical Group Co., Ltd (SHA: 605199) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its generic version of UCB Pharma’s Briviact (brivaracetam). The Category III injectable is in development for use as an adjuvant treatment…
-
CSPC Pharmaceutical Group Partners with Insilico and XtalPi for AI-Driven Drug R&D
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced strategic partnership agreements with Insilico Medicine Ltd and Shenzhen XtalPi (QuantumPharm, HKG: 2228). These collaborations will integrate artificial intelligence (AI) into the field of innovative drug research and development. Under the agreements, CSPC will utilize its drug R&D expertise alongside the…
-
Luye Pharma Group Submits Market Approval Filing for Lurbinectedin in Metastatic SCLC in Macau
•
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing has been submitted to Macau’s medical products administration bureau for the company’s drug lurbinectedin (LY01017). The targeted indication is for the treatment of metastatic small-cell lung cancer (SCLC) in patients who experience tumor progression during or after…
-
magAssist Receives FDA Breakthrough Device Designation for NyokAssist VAD
•
magAssist, a firm based in Suzhou, China, has announced that it has received breakthrough device designation from the US Food and Drug Administration (FDA) for its artificial heart product, the NyokAssist interventional ventricular assist device (VAD). The company highlights that this designation recognizes the cutting-edge design features of its innovative…
-
Auzone Biological Technology Gets FDA Approval for Edaravone Oral Preparations in ALS
•
Suzhou Auzone Biological Technology Co., Ltd. has received approval from the US Food and Drug Administration (FDA) to initiate a pivotal clinical study for its edaravone oral preparations in the treatment of amyotrophic lateral sclerosis (ALS). The Chinese company, which has a wholly owned subsidiary in Australia, is planning to…
-
RemeGen Ltd Reports 20.56% YOY Revenue Growth in H1 2023 Financial Results
•
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has released its financial report for the first half of 2023, recording revenues of RMB 422 million, an increase of 20.56% year-on-year (YOY). The company has also ramped up its research and development (R&D) costs to RMB 540 million, marking a 20.19% YOY…
-
Gilead’s Magrolimab Phase III Trial for AML Faces Partial Hold by FDA
•
Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration (FDA) has imposed a partial hold on recruitment for a Phase III trial of its investigational anti-CD47 biologic, magrolimab, in acute myeloid leukemia (AML). The company has not disclosed the reason behind the FDA’s decision but has indicated…
-
Ascentage Pharma’s 2023 Interim Report: 49% YOY Revenue Growth and Market Expansion
•
China-based Ascentage Pharma (HKG: 6855) has released its 2023 interim financial report, revealing a 49% year-on-year (YOY) increase in revenues, reaching RMB 143 million (USD 19.6 million). This growth was primarily driven by product sales and commercial cooperation. Olverembatinib’s Market Performance and Upcoming ApprovalsAscentage Pharma’s first marketed product, olverembatinib, generated…
-
Pfizer’s RSV Vaccine Abrysvo Receives FDA Authorization for Maternal Immunization
•
The US Food and Drug Administration (FDA) has authorized the use of Pfizer’s (NYSE: PFE) respiratory syncytial virus (RSV) vaccine, Abrysvo, for the prevention of lower respiratory tract disease (LRTD) and severe LRTD in infants through active immunization of pregnant women between 32 and 36 weeks of gestation. This marks…
-
J&J’s Teclistamab Granted Priority Review in China for Relapsed Multiple Myeloma
•
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson’s (J&J, NYSE: JNJ) teclistamab has been granted priority review for the treatment of recurrent or refractory multiple myeloma in China. The drug is being considered for conditional approval due to its breakthrough therapy designation (BTD) status, given…
-
Ascletis Pharma Inc. Reports 21.7% Revenue Increase in H1 2023, Led by Ritonavir Sales
•
China-based Ascletis Pharma Inc., (HKG: 1672) has revealed revenues of RMB 46.51 million (USD 6.38 million) for the first half of 2023, marking a 21.7% increase year-on-year. The significant growth was primarily driven by Ritonavir, which contributed RMB 44.17 million, representing a substantial 6291.8% YOY increase. Ritonavir’s Impact and Pfizer…
-
New Horizon Health Ltd Reports 264.6% YOY Revenue Increase and First Recurring Profits
•
China-based New Horizon Health Ltd (HKG: 6606), a leading cancer diagnostics developer, has released its audited interim financial report for the period ended June 30, 2023. The company reported revenues of RMB 820 million (USD 112 million), marking a significant increase of 264.6% year-on-year (YOY). This period also saw the…
-
Amgen’s Lumakras Faces Full Registration Review by FDA for KRAS-Mutated NSCLC
•
The US Food and Drug Administration (FDA) is scheduled to review an application submitted by Amgen (NASDAQ: AMGN) for the full registration of its pioneering KRASG12C inhibitor, Lumakras (sotorasib), in October this year. The treatment targets locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). Amgen announced this…
-
AstraZeneca’s Forxiga Demonstrates Clinical Benefits in Heart Failure and COPD Patients
•
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced evidence that its SGLT2 inhibitor, Forxiga (dapagliflozin), provides significant clinical benefits in patients with heart failure (HF) with preserved ejection fraction (pEF) and chronic obstructive pulmonary disease (COPD). This announcement highlights the potential of Forxiga in treating these conditions and underscores…
-
Novartis Sets Tentative Date for Sandoz Spin-Off, Targets October 4
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced October 4 of this year as the tentative date for the complete spin-off of its generics and biosimilars subsidiary, Sandoz (FRA: D8Y0). Prior to this, a crucial shareholder meeting is scheduled for September 15, where a vote will be held on the…
-
Jiangsu Hengrui Pharmaceuticals Reports 9.19% YOY Revenue Growth in H1 2023 Financial Report
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has released its financial report for the first half of 2023, reporting revenues of RMB 11.168 billion (USD 1.53 billion), marking a 9.19% increase year-on-year (YOY). The contribution from innovative drugs to this total was RMB 4.962 billion (USD 680 million). The company…
-
Hua Medicine Achieves Development Milestone for HuaTangNing with Bayer Agreement
•
China-based Hua Medicine (HKG: 2552) has announced the achievement of a significant development milestone for its diabetes treatment, HuaTangNing (dorzagliatin tablets, HMS5552). According to the terms of the 2020 collaboration agreement with Bayer AG (ETR: BAYN) focused on dorzagliatin, Hua is now eligible to receive a new milestone payment of…
-
MSD’s Welireg Meets Primary Endpoint in Phase III RCC Study but Misses OS Milestone
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed that the ongoing Phase III study evaluating the first-in-class HIF-2α inhibitor Welireg (belzutifan) in previously treated advanced renal cell carcinoma (RCC) has shown statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to everolimus, meeting its primary endpoint. However,…
